Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 15:71:12473.
doi: 10.3389/abp.2024.12473. eCollection 2024.

Clinical efficacy of different androgen deprivation therapies for prostate cancer and evaluation based on dynamic-contrast enhanced magnetic resonance imaging

WenXiao Guo  1 , MengZhu Li  1
Affiliations

Clinical efficacy of different androgen deprivation therapies for prostate cancer and evaluation based on dynamic-contrast enhanced magnetic resonance imaging

WenXiao Guo et al. Acta Biochim Pol. .

Abstract

Objective: To evaluate the clinical efficacy of different androgen deprivation therapies for prostate cancer (PCa) based on dynamic-contrast enhanced magnetic resonance imaging (DCE-MRI).

Methods: 104 patients with PCa were studied, all of whom were treated with androgen deprivation therapy. The patients were divided into a continuous group (continuous androgen deprivation therapy) and an intermittent group (intermittent androgen deprivation therapy) by random number table method, 52 cases/group. The therapeutic effect and DCE-MRI indices were compared and the relationship between DCE-MRI indices and clinical efficacy and the evaluation value of therapeutic efficacy were analyzed.

Results: The objective response rate (ORR) of the intermittent group was higher than that of the continuous group (p < 0.05), and there was no significant difference in disease control rate (DCR) between the two groups (p > 0.05). After treatment, volume transfer coefficient (Ktrans), reverse transfer constant (Kep), volume fraction (Ve), blood volume (BV), and blood flow (BF) in both groups were lowered, and those in the intermittent group were lower than the continuous group (p < 0.05). Ktrans, Kep, Ve, BF, and BV in the ORR group were lower than those in the non-ORR group (p < 0.05). Ktrans, Kep, Ve, BF, and BV were correlated with the therapeutic effect of PCa (p < 0.05). The AUC value of the combined detection of DCE-MRI indices in evaluating the therapeutic effect of PCa was greater than that of each index alone (p < 0.05).

Conclusion: Compared with continuous androgen deprivation therapy, intermittent androgen deprivation therapy has better clinical efficacy in the treatment of PCa, and DCE-MRI indices are related to the treatment efficacy of PCa and have an evaluation value.

Keywords: DCE-MRI; clinical effect; continuous androgen deprivation therapy; intermittent androgen deprivation therapy; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
DCE-MRI indices (Compared with the group before treatment, *p < 0.05; Compared with the continuous group, #p < 0.05.).
FIGURE 2
FIGURE 2
DCE-MRI indices in patients with different therapeutic effects (Compared with ORR group, *p < 0.05.).
FIGURE 3
FIGURE 3
ROC curve of DCE-MRI to evaluate the therapeutic effect of PCa.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Al Salmi I., Menezes T., El-Khodary M., Monteiro S., Haider E. A., Alabousi A. (2020). Prospective evaluation of the value of dynamic contrast enhanced (DCE) imaging for prostate cancer detection, with pathology correlation. Can. J. Urol. 27 (3), 10220–10227. Epub 2020/06/17. - PubMed
    1. Arnoldner M. A., Polanec S. H., Lazar M., Noori Khadjavi S., Clauser P., Pötsch N., et al. (2022). Rectal preparation significantly improves prostate imaging quality: assessment of the PI-QUAL score with visual grading characteristics. Eur. J. Radiology 147, 110145. Epub 2022/01/11. 10.1016/j.ejrad.2021.110145 - DOI - PubMed
    1. Bianchi S., Mosca A., Dalla Volta A., Prati V., Ortega C., Buttigliero C., et al. (2021). Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: a multicentre, randomised phase III study by the piemonte oncology network. Eur. J. Cancer 155, 127–135. 10.1016/j.ejca.2021.06.034 - DOI - PubMed
    1. Briones Carvajal J. R., Naimi M. F., Zhang L., Emmenegger U. (2021). Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 39 (6_Suppl. l), 133. 10.1200/jco.2021.39.6_suppl.133 - DOI
    1. Cereser L., Giannarini G., Bonato F., Pizzolitto S., Como G., Valotto C., et al. (2022). Comparison of multiple abbreviated multiparametric MRI-derived protocols for the detection of clinically significant prostate cancer. Minerva Urol. Nephrol. 74 (1), 29–37. Epub 2020/10/06. 10.23736/s2724-6051.20.03952-1 - DOI - PubMed